Skip to main content
. Author manuscript; available in PMC: 2012 Nov 8.
Published in final edited form as: Chembiochem. 2011 Mar 1;12(6):914–921. doi: 10.1002/cbic.201000563

Figure 5.

Figure 5

IGF1R juxtamembrane domain analogs selectively inhibited IGF-1, but not insulin-induced AKT activation in breast cancer cells. AKT activity in cell lysates was determined with the help of the Omni fluorogenic peptide substrate after 20 min incubation with IGF-1 (25 ng/ml) or insulin. A non-optimized analogue of insulin receptor juxtamembrane domain IR-2 (Pal-RQPDGPLGPLY-NH2) was used as a positive control in inhibition of insulin-induced AKT activation.